Clinical Trial Update: Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial updates the evaluation of carboplatin and etoposide with or without SHR-1316 in untreated extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• SHR-1316

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN